I have the full paper rather than the abstract, and the supplementary appendix.
I have the document in front of me and I can read the numbers. What I cannot do is interpret them.
I am reasonably comfortable with statistics and completely uncomfortable with chromatography, or vice versa.
Which parts of this are informative and which are decoration?
This is answerable from the trial data, but the effect sizes are modest enough that individual variation dominates.
Triglyceride reductions of twenty to thirty per cent are commonly reported in the trials in this class, with the largest reductions in those starting highest, which is the usual regression pattern plus a real effect.
| Quantity | Value | Derivation |
|---|---|---|
| Control-arm event rate | 8.0 % | From the trial table, not the abstract |
| Hazard ratio | 0.80 | Reported |
| Treated event rate | 6.4 % | 8.0 × 0.80 |
| Absolute risk reduction | 1.6 pp | 8.0 − 6.4 |
| Number needed to treat | 63 | 1 ÷ 0.016 |
| Relative risk reduction | 20 % | 1 − 0.80 |
The last two rows describe the same finding. Only one of them is used in headlines.
HDL cholesterol rises modestly with weight loss, and the outcome evidence for raising HDL pharmacologically is poor enough that the number is best treated as a marker rather than a target.
The Friedewald equation's bias at elevated triglycerides is well documented, and several corrected equations exist for exactly this reason.
Ask for apolipoprotein B alongside the standard panel. It costs little and it is the number that tracks risk.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsAsk PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.